Low-Level Laser Therapy for Diabetic Dermopathy in Patients With Type 2 Diabetes: A Placebo-Controlled Pilot Study

What the authors concluded

At the baseline, no significant differences existed between LLLT and placebo sides in the DD and skin blood flow at the knee and ankle sites (P >0.05). Post-intervention, a significant improvement occurred in DD diameter and the skin blood flow of the knee and ankle sites in the LLLT side (P <0.05), while the placebo side showed a significant improvement only in DD diameter (P <0.05) and non-si

Devices that emit this wavelength

Matched on wavelength within 15nm, since LED bins vary by roughly that much and a tighter match would be false precision. Where we have an irradiance figure, the session length is the time needed to reach this study's dose of 2.5 J/cm² at that intensity.

Matching a wavelength is not the same as reproducing a trial. Session times assume the device's published irradiance is accurate at the distance it was measured, which on brand-claim figures is often optimistic. Where a device publishes both a peak and an average we use the average, and where it publishes a falloff curve we use the lowest figure, so these times run long rather than short. Clinical protocols also control for spot size, contact and skin type in ways a home device cannot.